Trade Crinetics Pharmaceuticals Inc - CRNX CFD

Crinetics Pharma Company profile

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. It has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. Its CRN04777 is in clinical development for congenital hyperinsulinism. Its CRN04894 is in clinical development for diseases of excess adrenocorticotrophic hormone. The Company is advancing additional product candidates through preclinical discovery and development studies.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Crinetics Pharmaceuticals Inc revenues decreased from $71K to $0K. Net loss increased 47% to $76.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 45% to $52.9M (expense), Stock-based Compensation in R&D increase of 83% to $6.7M (expense).